MB
Matthew Biegler Oppenheimer Latest Price Targets & Analyst Ratings
Main Sector
Healthcare
Ratings Past Year
21
Avg Return
Past Year
Past Year
30%
Success Rate
Past Year
Past Year
0
%
Rating Distribution
Past Year
Positive
100%
Neutral
0%
Negative
0%
Past Week
Past Month
Past 3 Months
Past 6 Months
Past Year
All Time
Positive
Neutral
Negative
Large Cap
$10B to $200B
Mid Cap
$2B to $10B
Small Cap
$250M to $2B
Micro Cap
Under $250M
Financials
Healthcare
Financials
Asset Management
Healthcare
Biotechnology
Drug Manufacturers - General
| Stock | Rating | Price Target |
Upside Downside |
Ratings 1 Year |
Avg Return 1 Year |
Success Rate 1 Year | Date | |
|---|---|---|---|---|---|---|---|---|
|
Outperform
Maintained
| $48 |
77%
upside
| 5 | +66% |
0
%
| 11 Dec ‘25 1 month ago |
|
|
|
Outperform
Initiated
| $45 |
66%
upside
| 1 | -11% |
0
%
| 4 Dec ‘25 1 month ago |
|
|
|
Outperform
Maintained
| $15 |
24%
upside
| 2 | +57% |
0
%
| 14 Nov ‘25 2 months ago |
|
|
|
Outperform
Maintained
| $22 |
93%
upside
| 2 | +9.3% |
0
%
| 13 Nov ‘25 2 months ago |
|
|
|
Outperform
Maintained
| $28 |
46%
upside
| 3 | +19% |
0
%
| 10 Oct ‘25 3 months ago |
|
|
|
Outperform
Maintained
| $8 |
304%
upside
| 3 | +3.8% |
0
%
| 14 Aug ‘25 5 months ago |
|
|
|
Outperform
Initiated
| $7 |
30%
upside
| 1 | +132% |
0
%
| 31 Jul ‘25 5 months ago |
|
|
|
Outperform
Maintained
| $9 |
452%
upside
| 1 | +44% |
0
%
| 14 May ‘25 8 months ago |
|
|
|
Outperform
Reiterated
| $160 |
916%
upside
| 1 | -7.6% |
0
%
| 21 Mar ‘25 10 months ago |
|
|
|
Outperform
Maintained
| $30 |
900%
upside
| 1 | -40% |
0
%
| 11 Mar ‘25 10 months ago |
|
|
|
Outperform
Maintained
| $45 |
269%
upside
| 1 | -31% |
0
%
| 12 Feb ‘25 11 months ago |
|